Needham raised the firm’s price target on Doximity (DOCS) to $75 from $67 and keeps a Buy rating on the shares. The company reported strong Q1 results highlighted by early success in the upsell season, driven by new products, the analyst tells investors in a research note. The firm is especially bullish on Doximity’s two new AI innovations, Scribe and Pathway, which extend its functionality with offerings that are in high demand among physicians in 2025, Needham added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $62 from $60 at Morgan Stanley
- Doximity price target raised to $75 from $65 at Raymond James
- Doximity price target raised to $65 from $62 at Wells Fargo
- Doximity price target raised to $59 from $50 at Canaccord
- Doximity’s Strong Q1 and AI Innovations Drive Buy Rating Despite Growth Concerns